Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines
Autor Tom Brodyen Limba Engleză Hardback – 14 mar 2016
- Contains new and fully revised material on key topics such as biostatistics, biomarkers, orphan drugs, biosimilars, drug regulations in Europe, drug safety, regulatory approval and more
- Extensively covers the "study schema" and related features of study design
- Incorporates laboratory data from studies on human patients to provide a concrete tool for understanding the concepts in the design and conduct of clinical trials
- Includes decisions made by FDA reviewers when granting approval of a drug as real world learning examples for readers
Preț: 514.46 lei
Preț vechi: 666.53 lei
-23% Nou
Puncte Express: 772
Preț estimativ în valută:
98.45€ • 102.16$ • 82.29£
98.45€ • 102.16$ • 82.29£
Carte tipărită la comandă
Livrare economică 08-22 martie
Livrare express 11-15 februarie pentru 214.93 lei
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128042175
ISBN-10: 0128042176
Pagini: 896
Ilustrații: Approx. 100 illustrations
Dimensiuni: 191 x 235 x 46 mm
Greutate: 1.95 kg
Ediția:2. Auflage.
Editura: ELSEVIER SCIENCE
ISBN-10: 0128042176
Pagini: 896
Ilustrații: Approx. 100 illustrations
Dimensiuni: 191 x 235 x 46 mm
Greutate: 1.95 kg
Ediția:2. Auflage.
Editura: ELSEVIER SCIENCE
Public țintă
Researchers, physicians, nurses, pharmacists who plan and run clinical trials, members of the American Medical Writers Association, pharmaceutical and biotechnology industry scientists, pharmacology and pharmaceutical science students, pharmacy students and medical studentsCuprins
1. The Origins of Drugs
2. Introduction to Clinical Trial Design
3. Run-in Period
4. Inclusion/Exclusion Criteria, Stratification and Subgroups – Part I
5. Inclusion and Stratification Criteria – Part II
6. Randomization, Allocation, and Binding
7. Intent to Treat Analysis vs. Per Protocol Analysis
8. Biostatistics – Part I
9. Biostatistics – Part II
10. Introduction to Endpoints for Clinical Trials in Pharmacology
11. Endpoints in Clinical Trials on Solid Tumors – Objective Response
12. Oncology Endpoints: Overall Survival and Profession-Free Survival
13. Oncology Endpoints: Time to Progression
14. Oncology Endpoint: Disease-Free Survival
15. Oncology Endpoint: Time to Distant Metastasis
16. Neoadjuvant Therapy vs. Adjuvant Therapy
17. Hematological Cancers
18. Biomarkers and Personalized Medicine
19. Endpoints in Immune Diseases
20. Endpoints in Clinical Trials on Infections
21. Health-Related Quality of Life
22. Health-Related Quality of Life Instruments for Immune Disorders
23. Health-Related Quality of Life Instruments and Infections
24. Drug Safety
25. Mechanisms of Action, Part I
26. Mechanisms of Action, Part II – Cancer
27. Mechanisms of Action, Part III – Immune Disorders
28. Mechanisms of Action, Part IV- Infections
29. Consent Forms
30. Package Inserts
31. Regulatory Approval
32. Patents
2. Introduction to Clinical Trial Design
3. Run-in Period
4. Inclusion/Exclusion Criteria, Stratification and Subgroups – Part I
5. Inclusion and Stratification Criteria – Part II
6. Randomization, Allocation, and Binding
7. Intent to Treat Analysis vs. Per Protocol Analysis
8. Biostatistics – Part I
9. Biostatistics – Part II
10. Introduction to Endpoints for Clinical Trials in Pharmacology
11. Endpoints in Clinical Trials on Solid Tumors – Objective Response
12. Oncology Endpoints: Overall Survival and Profession-Free Survival
13. Oncology Endpoints: Time to Progression
14. Oncology Endpoint: Disease-Free Survival
15. Oncology Endpoint: Time to Distant Metastasis
16. Neoadjuvant Therapy vs. Adjuvant Therapy
17. Hematological Cancers
18. Biomarkers and Personalized Medicine
19. Endpoints in Immune Diseases
20. Endpoints in Clinical Trials on Infections
21. Health-Related Quality of Life
22. Health-Related Quality of Life Instruments for Immune Disorders
23. Health-Related Quality of Life Instruments and Infections
24. Drug Safety
25. Mechanisms of Action, Part I
26. Mechanisms of Action, Part II – Cancer
27. Mechanisms of Action, Part III – Immune Disorders
28. Mechanisms of Action, Part IV- Infections
29. Consent Forms
30. Package Inserts
31. Regulatory Approval
32. Patents